

1 The prevalence of chronic kidney disease 2 in people with severe mental illness: A 3 systematic review protocol

4 Carswell, C.¹, Bramham, K.², Chilcot, J.³, Jacobs, R.,⁴ Osborn, D.⁵, and Siddiqi, N.^{1,6,7}

5

6 ¹Department of Health Sciences, University of York, York, UK

7 ²King's College Hospital NHS Trust, London, UK

8 ³Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

9 ⁴Centre for Health Economics, University of York, York, UK

10 ⁵Division of Psychiatry, University College London, London, United Kingdom

11 ⁶Hull York Medical School, York, UK

12 ⁷Bradford District Care NHS Foundation Trust, Bradford, UK

13

14 Abstract

15 Background

16 People with severe mental illness (SMI) are more likely to develop long-term physical health
17 conditions, including type 2 diabetes and cardiovascular disease, compared to people without SMI.

18 This contributes to an inequality in life expectancy known as the 'mortality gap'. Chronic kidney
19 disease (CKD) is a growing global health concern set to be the 5th leading cause of life-years lost by
20 2040. However, there is limited research exploring the relationship between CKD and SMI. This
21 systematic review will aim to examine the prevalence and incidence of CKD among people with SMI.

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Methods**

24 We will search Medline, Embase, PsycINFO, CINAHL, Scopus and Web of Science for primary
25 epidemiological research reporting the prevalence or incidence of CKD among people with SMI in
26 any setting. Retrieved records will be managed in Covidence and screened by two independent
27 reviewers. Data will be extracted from included studies using a piloted data extraction form, and the
28 quality of studies will be evaluated using the appropriate JBI Critical Appraisal Checklist. The
29 certainty of evidence will be assessed using the Grading of Recommendations, Assessment,
30 Development, and Evaluations (GRADE) approach. Data from the included studies will be narratively
31 synthesised. Meta-analyses will be conducted using random effects models to examine the
32 prevalence and incidence of CKD among people with SMI.

33

34 **Discussion**

35

36 There is limited research exploring the relationship between CKD and SMI, and this proposed
37 systematic review will be the first to examine the prevalence of CKD among people with SMI. This
38 review will highlight the extent of the problem and provide a foundation for future research to
39 improve health outcomes for people with SMI.

40

41

42

43

44

45

46 Introduction

47 People with severe mental illness (SMI; enduring conditions that can present with psychosis,
48 including schizophrenia and bipolar disorder) die, on average, 15-20 years earlier than people who
49 do not have SMI [1, 2]. This inequality, known as the mortality gap, is widening over time and is
50 largely driven by higher rates of long-term physical health conditions and associated poor outcomes
51 [1, 3]. The leading cause of death among people with SMI is cardiovascular disease, accounting for
52 70% of all deaths in people with either bipolar disorder or schizophrenia [4]. The risk of sudden
53 cardiac death or cardiovascular mortality is five times higher in people with SMI, compared to
54 people without SMI [4].

55

56 While research has explored the relationship between SMI and long-term conditions such as
57 cardiovascular disease [5] and type 2 diabetes [6], chronic kidney disease (CKD) has not received the
58 same attention [7]. CKD is a condition characterised by progressive loss of kidney function that can
59 eventually lead to kidney failure (CKD stage 5), requiring kidney replacement therapies such as a
60 transplant or dialysis [8]. The current global estimate for the prevalence of CKD is 843.6 million [9].
61 However, prevalence is increasing, and CKD is set to become the 5th leading cause of life-years lost
62 globally by 2040 [10].

63

64 There is evidence to suggest that people living with SMI could be at higher risk of developing CKD
65 [7]. Antipsychotic medication and mood stabilisers, commonly used in the treatment of SMI, can
66 induce metabolic syndrome, and increase the risk of diabetes mellitus and hypertension which are
67 the leading causes of CKD worldwide [11]. Lithium, a common mood stabiliser used in the treatment
68 of bipolar disorder, is nephrotoxic [12] , can induce acute kidney injury at high doses, and increases
69 the risk of CKD with long-term use [13]. Antipsychotic medications may also increase the risk of
70 developing CKD [14]. Although not known to be directly nephrotoxic, this risk likely results from the

71 significant cardiometabolic disturbances that can result as a side-effect of antipsychotic medication
72 [15], and the well-established relationship between CKD and poor cardiometabolic health [16]. In
73 addition, lifestyle and behavioural factors such as smoking [17], diets high in fat, salt and sugar [18],
74 and high levels of sedentary behaviour are known risk factors for CKD, while also being more
75 common among people with SMI [19-22].

76
77 Identifying people at risk of CKD is crucial to facilitate early identification and intervention [23]. Early
78 intervention can prevent or slow progression to the later stages of CKD, and reduce the risk of
79 cardiovascular mortality [24]. This is pertinent as cardiovascular complications are the leading cause
80 of death related to both CKD and SMI [25, 26], yet research suggests early intervention is not
81 occurring in this population. For example, people with SMI have lower rates of accessing nephrology
82 care [27], are less likely to receive dialysis [28, 29], and are less likely to be assessed for
83 transplantation when compared to people without SMI [30].

84
85 To advocate for improved identification and appropriate care for people with co-existing SMI and
86 CKD, there is a need to understand the epidemiology of this co-morbidity, including prevalence and
87 incidence. Therefore, a systematic review is needed to understand the extent of the problem and
88 provide a foundation for future research.

89 Objectives

90 This review has two overarching objectives:

- 91 ● Examine the prevalence and incidence of CKD among people with SMI.
- 92 ● Compare the prevalence and incidence of CKD among people with SMI, to those who do not
93 have SMI.

94 Material and Methods

95 This protocol has been prospectively registered on the PROSPERO database (ID: CRD42024527215)
96 [31] and is reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-
97 Analysis Protocols (PRISMA-P) statement [32].

98 Search strategy and information sources

99 We will search electronic databases, including Medline, Embase, PsycInfo, CINAHL, Scopus and Web
100 of Science from conception to June 2024. No restrictions on year of publication or publication status
101 will be applied during the initial searches, to enable exploration of prevalence and incidence across
102 time. All searches will be re-run before the final analysis to ensure all relevant publications are
103 included. Search strings for electronic databases were developed according to the exposure (severe
104 mental illness), outcome (chronic kidney disease) and study design (epidemiological designs). Search
105 terms were identified from relevant systematic reviews capturing similar concepts and were refined
106 through initial piloting and consultation with subject librarians. The full MEDLINE strategy can be
107 found in Appendix 1.

108

109 We will review reference lists of included articles, and seminal publications and search key journals
110 in the subject area to ensure all relevant publications have been identified. This will include the
111 Clinical Journal of the American Society of Nephrology, the International Journal of Nephrology,
112 JAMA Psychiatry, The Lancet Psychiatry, BMC Nephrology and BMC Psychiatry. We will also search
113 grey literature repositories including ProQuest Dissertations and Open Science Framework (OSF).
114 Experts in the field of severe mental illness and kidney disease, and authors of relevant studies, will
115 be consulted to identify any potential key publications that could have been missed in the initial
116 searches.

117 Eligibility criteria

118 Study design

119 Inclusion criteria

- 120 ● Epidemiological observational studies, including cohort, case-control and cross-sectional
121 studies will be included.

122

123 Exclusion criteria

- 124 ● Qualitative studies, randomised controlled trials, and quasi-experimental studies will be
125 excluded. While experimental studies may report the proportions of participants with
126 certain conditions, they are not designed to determine the prevalence or incidence of a
127 condition and often include super-selected samples which may not be representative of the
128 population. Therefore, they will be excluded.
- 129 ● Case reports, editorials, commentaries, and protocols will be excluded.

130 Population/ Exposure

131 Inclusion criteria

- 132 ● Adults aged 18 years and over
- 133 ● The population includes participants who have a diagnosis of SMI. SMI will be defined in this
134 review as psychiatric conditions that can present with psychosis (not induced by substances
135 or caused by an organic condition) [33-36]. These conditions include schizophrenia,
136 schizoaffective disorder, bipolar disorder, severe depression with psychosis, other specified
137 psychosis, and persistent delusional disorders. Any report of participants having a diagnosis
138 of these conditions, using any standardised diagnostic tool (including the International
139 Classification of Diseases (ICD) and the Diagnostic and Statistical Manual (DSM)) will be
140 included.

141

142 **Exclusion criteria**

- 143 ● Participants under the age of 18. If the study has also collected data from adults (over and
144 those under 18, it will be included if the data is presented separately and can be analysed
145 separately.
- 146 ● Studies which focus exclusively on conditions which do not meet the classification for SMI,
147 for example, anxiety disorders, depressive disorders which do not present with psychosis,
148 eating disorders, and personality disorders, will be excluded. Studies focused on depressive
149 disorders, in general, will only be included if they report results for severe depression with
150 psychosis separately. Studies which focus on a variety of mental health conditions will be
151 included if they report findings in a way that allows identification and separate analysis of
152 participants with SMI.
- 153 ● Studies, where different mental health diagnoses or categories are not reported separately
154 (for example, where results for participants with SMI are aggregated with participants who
155 have common mental disorders, such as depression or anxiety), will only be included if more
156 than 50% of the sample are known to have SMI.
- 157 ● Studies where the proportion of participants with SMI cannot be determined will be
158 excluded.

159 **Outcome**

160 **Inclusion criteria**

- 161 ● Studies which report the prevalence or incidence of CKD, at any stage, among people with
162 SMI.
- 163 ● Studies which compare the prevalence or incidence of CKD, at any stage, among the general
164 population (or those without SMI) to people with SMI.

165

166 Exclusion criteria

- 167 ● Studies which focus on the prevalence or incidence of acute kidney injury (AKI), without
168 reporting the prevalence or incidence of CKD, among people with SMI.
- 169 ● Studies which report the prevalence of SMI among people with CKD (where a population
170 with CKD is used as the denominator population or exposure, and SMI is reported as the
171 outcome).

172 Study selection

173 Records will be imported into Covidence for screening [37]. Two independent reviewers will
174 complete the title and abstract screening, and disagreements will be resolved through discussion. If
175 an agreement cannot be reached, the decision will be made by a third reviewer. Following title and
176 abstract screening the full texts of eligible studies will be imported into Covidence to undergo full-
177 text screening, which again will be completed by two independent reviewers, with disagreements
178 resolved through discussion or a decision from a third reviewer.

179 Data extraction

180 Two independent reviewers will perform the data extraction. A data extraction form will be
181 developed in Excel and initially piloted by the two reviewers on a subset of included studies to
182 ensure the form is fit for purpose. Disagreements and inconsistencies in data extraction will be
183 reviewed and discussed, and the initial data extraction form will be refined as needed. Following the
184 piloting, data extraction will be performed again by two reviewers, with any disagreements being
185 resolved by a third reviewer who has not previously been involved with the data extraction process.
186 Articles reporting data from the same study in different publications will be grouped at this stage
187 and presented within a single study. The data extraction form will capture the author's names, date
188 of publication(s), publication type(s), country, study design, total sample size, number of participants

189 with SMI, diagnoses, mean age, percentage of females, ethnicity, medication use, data collection
190 procedures, statistical approach, summary results (prevalence, incidence and comparisons), and
191 covariates considered.

192 Risk of bias assessment

193 Two independent reviewers will use the appropriate JBI (formerly Joanna Briggs Institute) Critical
194 Appraisal Checklist to evaluate the risk of bias in each of the included studies. The JBI Critical
195 Appraisal Checklists assess the trustworthiness and quality of published research and include
196 checklists for a range of different methodologies including cohort studies, case-control studies and
197 cross-sectional studies [38]. Any disagreement in the assessment of the two independent reviewers
198 will be settled through discussion, or if an agreement cannot be reached, through a decision made
199 by a third reviewer who has not previously been involved with the critical appraisal process.

200 Certainty of evidence

201 We will use the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE)
202 approach to determine the certainty of the evidence [39]. GRADE outlines five domains that are
203 assessed to determine certainty: risk of bias, inconsistency, indirectness, imprecision and publication
204 bias. GRADE is predominantly used to assess certainty in intervention research and has not been
205 formally adapted for the use in systematic reviews of prevalence or incidence. However, previous
206 systematic reviews have used GRADE to evaluate the certainty of prevalence studies with adapted
207 components [40]. We will use the GRADE guidance for baseline risk or overall prognosis, as
208 recommended by Borges Migliavaca et al. (2020) for systematic reviews of prevalence [41].

209 Data synthesis

210 The data from the included studies will be presented in tables and narratively synthesised to provide
211 a summary of the study characteristics and findings. Meta-analyses will also be conducted using
212 random effects models assuming an adequate number of studies (at least two) and clinical similarity
213 to justify the pooling of prevalence or incidence rate. The heterogeneity across studies will be
214 assessed through visual inspection of forest plots, a chi-squared test for heterogeneity, and the I^2
215 statistic. However, as meta-analyses of prevalence tend to have high I^2 statistics [42], we will not
216 apply statistical thresholds to determine whether it is appropriate to pool the data. We will
217 transform the raw proportions using the Freeman-Tukey variant of the arcsine square root
218 transformation [43]. For objective 1, the pooled prevalence or incidence rate of CKD among people
219 with SMI will be presented with 95% CIs. For objective 2, we will undertake a meta-analysis of
220 prevalence or incidence rate comparisons if the data is available. These will be presented as pooled
221 risk ratios or odds ratios, with 95% CIs. If there is sufficient data, we will conduct subgroup analyses
222 to explore the differences in CKD across different types of SMI diagnosis, CKD stage, medication,
223 gender, age, geography (Low- and middle- income countries or high-income countries), setting
224 (community or inpatient), and year of data collection.

225 Discussion

226 This proposed review aims to address a crucial gap in the evidence base by synthesising the
227 literature on the prevalence of CKD among people with SMI. Previous systematic reviews have
228 established that people with SMI are at significantly higher risk of developing long-term physical
229 health conditions, including type 2 diabetes [5, 6]. However, the available literature on the
230 prevalence or incidence of CKD has not yet been synthesised in a systematic review.

231 Implications for research, practice or policy

232 By examining the prevalence of CKD in people with SMI, this review will highlight the need for future
233 research and policy change. Most research to date in this population has focused on the role of
234 lithium as a risk factor for CKD [44], and there is limited research exploring other, potentially
235 modifiable, risk factors [7]. Establishing the prevalence of CKD among people with SMI (including
236 those not on lithium treatment) is an important step towards identifying key modifiable risk factors
237 that contribute to the development and progression of CKD in this population. This will enable not
238 just more targeted approaches to screening and monitoring to facilitate early intervention but could
239 also inform the development of future interventions to improve CKD outcomes for people with SMI.

240

241

242

243

244

245

246

247

248

249

250

251

252 References

253

- 254 1. Fiorillo A, Sartorius N. Mortality gap and physical comorbidity of people with severe
255 mental disorders: the public health scandal. *Annals of General Psychiatry*. 2021;20(1):52.
256 doi: [10.1186/s12991-021-00374-y](https://doi.org/10.1186/s12991-021-00374-y).
- 257 2. Siddiqi N, Doran T, Prady SL, Taylor J. Closing the mortality gap for severe mental
258 illness: Are we going in the right direction? *British Journal of Psychiatry*. 2017;211(3):130-1.
259 Epub 2018/01/02. doi: [10.1192/bjp.bp.117.203026](https://doi.org/10.1192/bjp.bp.117.203026).
- 260 3. Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with
261 bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. *Br J Psychiatry*.
262 2017;211(3):175-81. Epub 20170706. doi: [10.1192/bjp.bp.117.202606](https://doi.org/10.1192/bjp.bp.117.202606). PubMed PMID:
263 28684403; PubMed Central PMCID: [PMCPMC5579328](https://pubmed.ncbi.nlm.nih.gov/PMC5579328/).
- 264 4. Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe
265 mental illness. *Nature Reviews Cardiology*. 2021;18(2):136-45. doi: [10.1038/s41569-020-](https://doi.org/10.1038/s41569-020-00463-7)
266 [00463-7](https://doi.org/10.1038/s41569-020-00463-7).
- 267 5. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al.
268 Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and
269 specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and
270 113,383,368 controls. *World Psychiatry*. 2017;16(2):163-80. doi:
271 <https://doi.org/10.1002/wps.20420>.
- 272 6. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes
273 mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a
274 systematic review and large scale meta-analysis. *World Psychiatry*. 2016;15(2):166-74. doi:
275 <https://doi.org/10.1002/wps.20309>.
- 276 7. Carswell C, Cogley C, Bramham K, Chilcot J, Noble H, Siddiqi N. Chronic kidney
277 disease and severe mental illness: a scoping review. *Journal of Nephrology*.
278 2023;36(6):1519-47. doi: [10.1007/s40620-023-01599-8](https://doi.org/10.1007/s40620-023-01599-8).

- 279 8. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney
280 disease. *The Lancet*. 2021;398(10302):786-802. doi: [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)00519-5)
281 [6736\(21\)00519-5](https://doi.org/10.1016/S0140-6736(21)00519-5).
- 282 9. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. *Kidney Int*
283 *Suppl* (2011). 2022;12(1):7-11. Epub 20220318. doi: 10.1016/j.kisu.2021.11.003. PubMed
284 PMID: 35529086; PubMed Central PMCID: PMC69073222.
- 285 10. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al.
286 Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for
287 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and
288 territories. *Lancet*. 2018;392(10159):2052-90. Epub 20181016. doi: 10.1016/s0140-
289 6736(18)31694-5. PubMed PMID: 30340847; PubMed Central PMCID: PMC6227505.
- 290 11. Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic
291 kidney disease and the global public health agenda: an international consensus. *Nature*
292 *Reviews Nephrology*. 2024;20(7):473-85. doi: 10.1038/s41581-024-00820-6.
- 293 12. Grünfeld J-P, Rossier BC. Lithium nephrotoxicity revisited. *Nature Reviews*
294 *Nephrology*. 2009;5(5):270-6. doi: 10.1038/nrneph.2009.43.
- 295 13. Gupta S, Khastgir U. Drug information update. Lithium and chronic kidney disease:
296 debates and dilemmas. *BJPsych Bull*. 2017;41(4):216-20. doi: 10.1192/pb.bp.116.054031.
297 PubMed PMID: 28811917; PubMed Central PMCID: PMC65537577.
- 298 14. Højlund M, Lund LC, Herping JLE, Haastrup MB, Damkier P, Henriksen DP. Second-
299 generation antipsychotics and the risk of chronic kidney disease: a population-based case-
300 control study. *BMJ Open*. 2020;10(8):e038247. doi: 10.1136/bmjopen-2020-038247.
- 301 15. Abosi O, Lopes S, Schmitz S, Fiedorowicz JG. Cardiometabolic effects of
302 psychotropic medications. *Horm Mol Biol Clin Investig*. 2018;36(1). Epub 20180110. doi:
303 10.1515/hmbci-2017-0065. PubMed PMID: 29320364; PubMed Central PMCID:
304 PMC6818518.

- 305 16. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al.
306 Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart
307 Association. *Circulation*. 2023;148(20):1606-35. doi: 10.1161/CIR.0000000000001184.
- 308 17. Fu YC, Xu ZL, Zhao MY, Xu K. The Association Between Smoking and Renal
309 Function in People Over 20 Years Old. *Front Med (Lausanne)*. 2022;9:870278. Epub
310 20220603. doi: 10.3389/fmed.2022.870278. PubMed PMID: 35721101; PubMed Central
311 PMCID: PMC9205397.
- 312 18. Kuma A, Kato A. Lifestyle-Related Risk Factors for the Incidence and Progression of
313 Chronic Kidney Disease in the Healthy Young and Middle-Aged Population. *Nutrients*.
314 2022;14(18). Epub 20220914. doi: 10.3390/nu14183787. PubMed PMID: 36145162;
315 PubMed Central PMCID: PMC9506421.
- 316 19. Dickerson F, Schroeder J, Katsafanas E, Khushalani S, Origoni AE, Savage C, et al.
317 Cigarette Smoking by Patients With Serious Mental Illness, 1999–2016: An Increasing
318 Disparity. *Psychiatric Services*. 2017;69(2):147-53. doi: 10.1176/appi.ps.201700118.
- 319 20. Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M, et al.
320 Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder
321 and major depressive disorder: a global systematic review and meta-analysis. *World*
322 *Psychiatry*. 2017;16(3):308-15. doi: <https://doi.org/10.1002/wps.20458>.
- 323 21. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The
324 dietary pattern of patients with schizophrenia: A systematic review. *Journal of Psychiatric*
325 *Research*. 2013;47(2):197-207. doi: <https://doi.org/10.1016/j.jpsychires.2012.10.005>.
- 326 22. Teasdale SB, Ward PB, Samaras K, Firth J, Stubbs B, Tripodi E, et al. Dietary intake
327 of people with severe mental illness: systematic review and meta-analysis. *The British*
328 *Journal of Psychiatry*. 2019;214(5):251-9. Epub 2019/02/20. doi: 10.1192/bjp.2019.20.
- 329 23. Okpechi IG, Caskey FJ, Gaipov A, Tannor EK, Noubiap JJ, Effa E, et al. Early
330 Identification of CKD-A Scoping Review of the Global Populations. *Kidney Int Rep*.
331 2022;7(6):1341-53. Epub 20220406. doi: 10.1016/j.ekir.2022.03.031. PubMed PMID:
332 35685314; PubMed Central PMCID: PMC9171699.

- 333 24. Neuen BL, Jun M, Wick J, Kotwal S, Badve SV, Jardine MJ, et al. Estimating the
334 population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic
335 kidney disease: a cross-sectional observational study using routinely collected Australian
336 primary care data. *The Lancet Regional Health – Western Pacific*. 2024;43. doi:
337 [10.1016/j.lanwpc.2023.100988](https://doi.org/10.1016/j.lanwpc.2023.100988).
- 338 25. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic
339 Kidney Disease. *Circulation*. 2021;143(11):1157-72. doi:
340 [10.1161/CIRCULATIONAHA.120.050686](https://doi.org/10.1161/CIRCULATIONAHA.120.050686).
- 341 26. de Mooij LD, Kikkert M, Theunissen J, Beekman ATF, de Haan L, Durkoop P, et al.
342 Dying Too Soon: Excess Mortality in Severe Mental Illness. *Front Psychiatry*. 2019;10:855.
343 Epub 20191206. doi: [10.3389/fpsy.2019.00855](https://doi.org/10.3389/fpsy.2019.00855). PubMed PMID: 31920734; PubMed Central
344 PMCID: PMCPMC6918821.
- 345 27. Hsu Y-H, Cheng J-S, Ouyang W-C, Lin C-L, Huang C-T, Hsu C-C. Lower Incidence
346 of End-Stage Renal Disease but Suboptimal Pre-Dialysis Renal Care in Schizophrenia: A
347 14-Year Nationwide Cohort Study. *PLOS ONE*. 2015;10(10):e0140510. doi:
348 [10.1371/journal.pone.0140510](https://doi.org/10.1371/journal.pone.0140510).
- 349 28. Boyle SM, Fehr K, Deering C, Raza A, Harhay MN, Malat G, et al. Barriers to kidney
350 transplant evaluation in HIV-positive patients with advanced kidney disease: A single-center
351 study. *Transplant Infectious Disease*. 2020;22(2):e13253. doi:
352 <https://doi.org/10.1111/tid.13253>.
- 353 29. Tzur Bitan D, Krieger I, Berkovitch A, Comaneshter D, Cohen A. Chronic kidney
354 disease in adults with schizophrenia: A nationwide population-based study. *General Hospital
355 Psychiatry*. 2019;58:1-6. doi: <https://doi.org/10.1016/j.genhosppsych.2019.01.007>.
- 356 30. Bayat S, Frimat L, Thilly N, Loos C, Briançon S, Kessler M. Medical and non-medical
357 determinants of access to renal transplant waiting list in a French community-based network
358 of care. *Nephrology Dialysis Transplantation*. 2006;21(10):2900-7. doi: [10.1093/ndt/gfl329](https://doi.org/10.1093/ndt/gfl329).

- 359 31. Carswell CC, Joseph; Jacobs, Rowena; Siddiqi, Najma; Osborn, David. The
360 prevalence of chronic kidney disease amongst people with severe mental illness: a
361 systematic review and meta-analysis.: PROSPERO; 2024.
- 362 32. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred
363 reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015
364 statement. *Systematic Reviews*. 2015;4(1):1. doi: 10.1186/2046-4053-4-1.
- 365 33. Reilly S, Olier I, Planner C, Doran T, Reeves D, Ashcroft DM, et al. Inequalities in
366 physical comorbidity: a longitudinal comparative cohort study of people with severe mental
367 illness in the UK. *BMJ Open*. 2015;5(12):e009010. doi: 10.1136/bmjopen-2015-009010.
- 368 34. Osborn DPJ, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of
369 diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe
370 mental illnesses: Systematic review and metaanalysis. *BMC Psychiatry*. 2008;8(1):84. doi:
371 10.1186/1471-244X-8-84.
- 372 35. Das-Munshi J, Chang C-K, Dutta R, Morgan C, Nazroo J, Stewart R, et al. Ethnicity
373 and excess mortality in severe mental illness: a cohort study. *The Lancet Psychiatry*.
374 2017;4(5):389-99. doi: 10.1016/S2215-0366(17)30097-4.
- 375 36. Taylor J, Stubbs B, Hewitt C, Ajjan RA, Alderson SL, Gilbody S, et al. The
376 Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving
377 Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-
378 Analysis. *PLOS ONE*. 2017;12(1):e0168549. doi: 10.1371/journal.pone.0168549.
- 379 37. Innovation. VH. Covidence systematic review software.
- 380 38. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for
381 systematic reviews of observational epidemiological studies reporting prevalence and
382 cumulative incidence data. *Int J Evid Based Healthc*. 2015;13(3):147-53. doi:
383 10.1097/xeb.0000000000000054. PubMed PMID: 26317388.
- 384 39. Schünemann HB, Jan; Guyatt, Gordon; Oxman, Andrew. *GRADE Handbook 2013*.
385 Available from: <https://gdt.gradepro.org/app/handbook/handbook.html>.

- 386 40. Edwards J, Hayden J, Asbridge M, Gregoire B, Magee K. Prevalence of low back
387 pain in emergency settings: a systematic review and meta-analysis. BMC Musculoskeletal
388 Disorders. 2017;18(1):143. doi: 10.1186/s12891-017-1511-7.
- 389 41. Borges Migliavaca C, Stein C, Colpani V, Barker TH, Munn Z, Falavigna M. How are
390 systematic reviews of prevalence conducted? A methodological study. BMC Med Res
391 Methodol. 2020;20(1):96. Epub 20200426. doi: 10.1186/s12874-020-00975-3. PubMed
392 PMID: 32336279; PubMed Central PMCID: PMC7184711.
- 393 42. Migliavaca CB, Stein C, Colpani V, Barker TH, Ziegelmann PK, Munn Z, et al. Meta-
394 analysis of prevalence: statistic and how to deal with heterogeneity. Research Synthesis
395 Methods. 2022;13(3):363-7. doi: <https://doi.org/10.1002/jrsm.1547>.
- 396 43. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for
397 systematic reviews of observational epidemiological studies reporting prevalence and
398 cumulative incidence data. JBI Evidence Implementation. 2015;13(3).
- 399 44. Schoretsanitis G, de Filippis R, Brady BM, Homan P, Suppes T, Kane JM.
400 Prevalence of impaired kidney function in patients with long-term lithium treatment: A
401 systematic review and meta-analysis. Bipolar Disorders. 2022;24(3):264-74. doi:
402 <https://doi.org/10.1111/bdi.13154>.

403

404

405

406

407

408

409 Appendix 1

- 410 1. Exp Renal Dialysis/
- 411 2. h?emodialysis.tw,kf.
- 412 3. h?emofiltration.tw,kf.
- 413 4. h?emodiafiltration.tw,kf.
- 414 5. dialysis.tw,kf.
- 415 6. (Peritoneal adj1 (dialysis)).tw,kf.
- 416 7. (PD or CAPD or CCPD or APD).tw,kf.
- 417 8. Exp Renal Insufficiency/
- 418 9. Exp Kidney Failure/
- 419 10. Exp Renal Insufficiency, Chronic/
- 420 11. Exp Kidney Diseases/
- 421 12. Uremia/
- 422 13. (endstage adj1 (renal or kidney)).tw,kf
- 423 14. (ESRF or ESKF or ESRD or ESKD).tw,kf
- 424 15. (chronic adj1 (kidney or renal)).tw,kf
- 425 16. (CKF or CKD or CRF or CRD).tw,kf.
- 426 17. (predialysis).tw,kf.
- 427 18. (renal adj1 (transplant* or graft)).tw,kf.
- 428 19. (kidney adj1 (transplant* or graft)).tw,kf.
- 429 20. (1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16
- 430 OR 17 OR 18 OR 19)
- 431 21. Exp Schizophrenia/
- 432 22. Exp Affective disorders, psychotic/
- 433 23. Exp Bipolar disorder/

- 434 24. (bipolar adj1 (disorder* or disease* or illness*)).tw,kf.
- 435 25. paranoid disorders/
- 436 26. Exp psychotic disorders/
- 437 27. schizo*.tw,kf.
- 438 28. (mani* adj3 depress*).tw,kf.
- 439 29. (psychotic* adj3 depress*).tw,kf.
- 440 30. (severe* adj3 affective*).tw,kf.
- 441 31. (severe* adj3 mental*).tw,kf.
- 442 32. (severe* adj3 depress*).tw,kf.
- 443 33. (psychos#s adj3 depress*).tw,kf.
- 444 34. (serious* adj3 affective*).tw,kf.
- 445 35. "serious mood".tw,kf.
- 446 36. (serious* adj3 mental*).tw,kf.
- 447 37. (serious* adj3 depress*).tw,kf.
- 448 38. "Severe mental".tw,kf.
- 449 39. Severe adj1 (mental* or depress*).tw,kf.
- 450 40. "Schizoaffective disorder".tw,kf
- 451 41. Exp Antipsychotic Agents/
- 452 42. Exp Antimanic Agents/
- 453 43. Exp Psychotropic Drugs/
- 454 44. (21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR
- 455 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43)
- 456 45. Exp epidemiologic studies/
- 457 46. Exp epidemiology/
- 458 47. epidemiolog*.tw,kf.
- 459 48. Exp prevalence/

- 460 49. prevalence.tw,kf.
- 461 50. Exp incidence/
- 462 51. incidence.tw,kf.
- 463 52. Exp Observational Study/
- 464 53. observational.tw,kf.
- 465 54. Longitudinal Studies/
- 466 55. longitudinal.tw,kf.
- 467 56. Case-Control Studies/
- 468 57. Exp Cross-Sectional Studies/
- 469 58. Exp Cohort Studies/
- 470 59. "cohort".tw,kf.
- 471 60. Exp Risk/
- 472 61. Exp Risk Factors/
- 473 62. (45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 57 OR 58 OR
- 474 59 OR 60 OR 61)
- 475 63. (20 AND 44 AND 62)
- 476